Centiva Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Centiva Capital’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-27,312	Closed	-$202K	–	1814
2024 Q4	$202K	Buy	27,312 +10,687	+64%	+$99.1K	﹤0.01%	1363
2024 Q3	$156K	Buy	+16,625	New	+$158K	﹤0.01%	1894
2024 Q2	–	Sell	-11,030	Closed	-$163K	–	2281
2024 Q1	$163K	Buy	+11,030	New	+$128K	﹤0.01%	1524
2021 Q2	–	Sell	-9,897	Closed	-$313K	–	1495
2021 Q1	$313K	Buy	9,897 +4,894	+98%	+$203K	0.01%	741
2020 Q4	$232K	Buy	+5,003	New	+$199K	0.01%	737
2019 Q4	–	Sell	-14,341	Closed	-$261K	–	870
2019 Q3	$261K	Buy	+14,341	New	+$317K	0.02%	460

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Centiva Capital's IOVA Position: Q1 2025 in Review

Centiva Capital sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 27,312 shares — an estimated $202K sold.

Centiva Capital first reported a position in IOVA in Q3 2019 and held it in 6 quarters. The position peaked at $313K in Q1 2021. 301 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

Centiva Capital reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
Centiva Capital sold 27,312 Iovance Biotherapeutics shares in Q1 2025, an estimated $202K.
Centiva Capital first reported a position in Iovance Biotherapeutics in Q3 2019 and held it in 6 quarters.
Centiva Capital's Iovance Biotherapeutics position peaked at $313K in Q1 2021.
301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Centiva Capital's 13F filing for Q1 2025, filed 15 May 2025.